The law in 2026
In most of the world the classic psychedelics remain strictly controlled. United States federal law lists psilocybin, LSD, DMT, mescaline and ibogaine in Schedule I, the category for substances with a high potential for abuse and no currently accepted medical use in treatment. Nothing in 2026 changed that listing. The federal government did act on research. In April, Executive Order 14401 directed federal agencies to speed the review of psychedelic drugs for serious mental illness, and in July the FDA published final guidance for companies that design clinical trials with these drugs. Neither step changed any drug's legal schedule. Colorado and Oregon license supervised psilocybin programs under their own state laws, and psilocybin remains illegal under federal law in both states. New Mexico's legislature created a medical psilocybin program in 2025. The Act requires the state to implement it by December 31, 2027, and the Department of Health has stated a target of the end of 2026. Outside the United States the rules differ from country to country. This page describes the law. It is not legal advice, and it does not tell anyone what they may do where they live. Metanoia is a research and education nonprofit and does not supply any substance.
The harder question: who do these belong to?
Almost everything modern science "discovered" about psychedelics was known to Indigenous peoples for centuries, even millennia. That history carries a debt, and the field's record of repaying it is poor.
The shadow of María Sabina
A cautionary taleWhen the Mazatec healer María Sabina let an American visitor witness her mushroom ceremony in 1955, and he published it in Life magazine, her village was overrun with seekers. Her community denounced her for revealing the sacred. Her house was burned. She died in poverty. Researchers call it a "representational hangover", reducing a whole people to a proxy for a drug. It is the reason any serious psychedelic organization must build in reciprocity, credit, and respect for the source, rather than simply extracting from it.
Peyote: a plant, a right, and a limit
Do not touchThe peyote cactus is the clearest ethical line in the whole field. It is slow-growing and now listed as vulnerable, threatened by over-harvest and habitat loss. In U.S. law it is protected specifically for the Native American Church. And when broad decriminalization movements arose, Indigenous leaders asked that peyote be excluded, to protect both the plant and their exclusive religious right to it. Even synthetic mescaline is rejected by some practitioners as a violation of the cactus's sacredness. The lesson is humbling: sometimes the right ethical answer is to leave something alone.
Why cultivable sources come first
Metanoia studies the classic psychedelics as a family. Where the family differs most is sourcing. Psilocybin mushrooms grow fast and are easily cultivated, so research on them never depends on stripping wild populations. Peyote is the opposite case. Whatever the source, the peoples who kept this knowledge, the Mazatec among them, deserve full respect and credit.
That shapes a simple sourcing principle we hold across the family: prefer cultivable, sustainable sources over threatened or wild ones: mushrooms and fast-growing San Pedro cactus over slow-growing peyote, and, where the science supports it, pure or lab-grown compounds over harvesting a threatened animal, as with the 5-MeO-DMT toad. Honoring the source without appropriating it is not a footnote to the science. For us, it is a condition of doing the work at all.